np 12

Tideglusib (NP031112), a non-ATP competitive inhibitor of glycogen synthase kinase 3 (GSK-3), is with anti-inflammatory and neuroprotective activities.

AUNP-12, a new immune checkpoint modulator, is an inhibitor of the PD-1 pathway.

AUNP-12 TFA (NP-12 TFA) is a polypeptide antagonist in the pd-1 signaling pathway, which has the same antagonistic effect on pd-l1 and pd-l2, and can protect the proliferation and effector function of lymphocytes.

BNP (1-21), Pro (Human) is a 21-amino acid peptide and a form of B-Type Natriuretic Peptide (BNP), a cardiac natriuretic hormone that coexists with the homologous atrial natriuretic peptide in the heart's dual natriuretic peptide system. BNP plays a critical role in heart organogenesis and the transition to extrauterine life [1] [2] [3].

Atriopeptin III (rat) (ANP 127-150), a 24-amino acid atrial peptide, functions as a powerful vasodilator and natriuretic/diuretic agent, enhancing renal functions and reducing blood pressure in a rat model with ureter-obstructed kidneys. It is utilized in research concerning chronic renal failure [1].

Tat-QFNP12 is a peptide that combines a transcriptional transactivator (Tat) transmembrane domain with an inhibitor targeting the interaction between N-Myc downstream regulated gene 2 (NDRG2) and protein phosphatase Mg2+/Mn2+ dependent 1A (PPM1A). This compound effectively mitigates blood-brain barrier endothelial tight junction disruption caused by elevated levels of matrix metalloproteinase-9 (MMP-9), alleviates cerebral edema, and promotes spontaneous activity along with symmetric limb movement in a mouse model of subarachnoid hemorrhage induced by endovascular puncture. These benefits are observed at a dosage of 20 mg/kg.

AUNP-12 acetate is a polypeptide inhibitor of PD-1 that is equivalent to PD-1 and PD-2 in inhibiting lymphocyte proliferation and effector fuction, in addition to immune activation and antitumor activity.

TAT-QFNP12 is a peptide that inhibits NDRG2-PPM1A interaction, reduces Smad2/3 phosphorylation, decreases MMP-9 production in astrocytes, and mitigates blood-brain barrier disruption following subarachnoid hemorrhage (SAH).